In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding

Irbaz Bin Riaz, Ariela L. Marshall, Robert G. Badgett

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)JC21
JournalAnnals of internal medicine
Issue number4
StatePublished - Aug 18 2020
Externally publishedYes

Bibliographical note

Funding Information:
Bristol-Myers Squibb–Pfizer Alliance.

Cite this